<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119813">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543139</url>
  </required_header>
  <id_info>
    <org_study_id>bpcre2009</org_study_id>
    <nct_id>NCT01543139</nct_id>
  </id_info>
  <brief_title>Trial of Combined Cytidine and Creatine in the Treatment of the Bipolar Depression</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Combined Cytidine and Creatine in the Treatment of the Bipolar Depression: A Magnetic Resonance Spectroscopy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed research is aimed to investigate the efficacy and safety of the creatine and
      cytidine augmentation in treating bipolar depression and to evaluate changes in relevant
      brain biochemical metabolism using magnetic resonance spectroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in depressive symptom scores at 12 weeks</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in depressive symptom scores at 8 weeks</measure>
    <time_frame>Baseline and at 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in depressive symptom scores at 4 weeks</measure>
    <time_frame>Baseline and at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in depressive symptom scores at 1 week</measure>
    <time_frame>Baseline and at 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in manic symptom scores at 1 week</measure>
    <time_frame>Baseline and at 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in manic symptom scores at 4 weeks</measure>
    <time_frame>Baseline and at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in manic symptom scores at 8 weeks</measure>
    <time_frame>Baseline and at 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in manic symptom scores at 12 weeks</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in global function scores at 1 week</measure>
    <time_frame>Baseline and at 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in global function scores at 4 weeks</measure>
    <time_frame>Baseline and at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in global function scores at 8 weeks</measure>
    <time_frame>Baseline and at 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in global function scores at 12 weeks</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Valproate+Cytidine+Creatine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate+Cytidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Valproate+Cytidine+Creatine</intervention_name>
    <description>Valproate: 300mg/day, Cytidine: 1g every other day, Creatine: Week0-1: 3g/day Week1-12: 5g/day</description>
    <arm_group_label>Valproate+Cytidine+Creatine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Valproate+Cytidine</intervention_name>
    <description>Valproate: 300mg/day, Cytidine: 1g every other day</description>
    <arm_group_label>Valproate+Cytidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <description>Valproate: 300mg/day</description>
    <arm_group_label>Valproate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 65

          -  Diagnosis of bipolar depression as assessed by the Structured Clinical Interview for
             DSM-IV (SCID-IV)

          -  Individuals who provided written consent for participation

        Exclusion Criteria:

          -  Present or past use of drugs for bipolar depression

          -  Presence of any major physical or neurological illness (e.g., head trauma, epilepsy,
             seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease,
             narrow-angle glaucoma, drug hypersensitivity, etc.)

          -  Diagnosis of any Axis I disorder other than bipolar disorder or presence of symptoms
             requiring hospitalization

          -  Presence of borderline personality disorder or antisocial personality disorder

          -  Presence of alcohol or drug dependence

          -  Intelligence quotient below 80

          -  Contraindications to magnetic resonance imaging (e.g., pacemaker implantation,
             claustrophobia, etc.)

          -  Use of psychoactive medications that may affect brain imaging findings

          -  Women who are pregnant, breastfeeding, or planning pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junghyun H Lee, MD, MS</last_name>
    <phone>82-10-3453-1744</phone>
    <email>leejunghyun1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Hwa Hong, MD</last_name>
      <phone>82-2-740-8096</phone>
      <email>jhhong@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 6, 2012</lastchanged_date>
  <firstreceived_date>February 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo, MD, PhD, MMS</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
